麗珠醫藥(01513)：萊康奇塔單抗注射液上市許可申請獲國家藥品監督管理局受理

　　麗珠醫藥(01513)(滬:000513)公布，近日，麗珠醫藥集團股份控股子公司珠海市麗珠單抗生物技術收到國家藥品監督管理局核准簽發的《受理通知書》（受理號：CXSS2500144），麗珠單抗與北京鑫康合生物醫藥科技聯合開發的萊康奇塔單抗注射液境內生產藥品註冊上市許可申請獲國家藥監局受理。
《經濟通通訊社24日專訊》

【說說心理話】出任播道兒童之家院長29年，羅美珍：「最滿足是看到孩子們長大後有好好生活，切斷上一代帶來的壞影響。」► 即睇

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。